Cargando…

Serum GDF-15 Levels in Patients with Parkinson’s Disease, Progressive Supranuclear Palsy, and Multiple System Atrophy

Serum growth differentiation factor 15 (GDF-15) levels are elevated in patients with Parkinson’s disease (PD) and may help differentiate these patients from healthy individuals. We aimed to clarify whether serum GDF-15 levels can help differentiate PD from atypical parkinsonian syndromes and determi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyaue, Noriyuki, Yabe, Hayato, Nagai, Masahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535128/ https://www.ncbi.nlm.nih.gov/pubmed/37755357 http://dx.doi.org/10.3390/neurolint15030066

Ejemplares similares

Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson’s disease
por: Miyaue, Noriyuki, et al.
Publicado: (2023)

Pain in multiple system atrophy and progressive supranuclear palsy compared to Parkinson's disease
por: Kass-Iliyya, Lewis, et al.
Publicado: (2015)

Identification of multiple system atrophy mimicking Parkinson’s disease or progressive supranuclear palsy
por: Miki, Yasuo, et al.
Publicado: (2021)

Whole-Brain Atrophy Rate in Idiopathic Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy
por: Guevara, C., et al.
Publicado: (2016)

Advanced diffusion imaging to track progression in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy
por: Mitchell, Trina, et al.
Publicado: (2022)

Force Control Deficits in Individuals with Parkinson’s Disease, Multiple Systems Atrophy, and Progressive Supranuclear Palsy
por: Neely, Kristina A., et al.
Publicado: (2013)

The Assessment of Subregions in the Frontal Lobe May Be Feasible in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA)
por: Alster, Piotr, et al.
Publicado: (2022)

Polysomnographic and Clinical Parameters before and after Zonisamide Therapy for Parkinson's Disease
por: Miyaue, Noriyuki, et al.
Publicado: (2022)

Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy
por: Mori, Akio, et al.
Publicado: (2019)

Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALE
por: Payan, Christine A. M., et al.
Publicado: (2011)

Clinical Profile of Cognitive Decline in Patients with Parkinson's Disease, Progressive Supranuclear Palsy, and Multiple System Atrophy
por: Sulena,, et al.
Publicado: (2017)

Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy
por: Brown, Jesse A., et al.
Publicado: (2017)

The Use of Cerebellar Hypoperfusion Assessment in the Differential Diagnosis of Multiple System Atrophy with Parkinsonism and Progressive Supranuclear Palsy-Parkinsonism Predominant
por: Madetko-Alster, Natalia, et al.
Publicado: (2022)

Whole-Brain Atrophy Differences between Progressive Supranuclear Palsy and Idiopathic Parkinson’s Disease
por: Guevara, Carlos, et al.
Publicado: (2016)

Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy
por: Lee, Sang-Wook, et al.
Publicado: (2012)

Cortical Thickness, Surface Area and Volume Measures in Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy
por: Worker, Amanda, et al.
Publicado: (2014)

Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson’s Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy
por: Rogozinski, Sophia, et al.
Publicado: (2022)

Speech acoustic indices for differential diagnosis between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy
por: Daoudi, Khalid, et al.
Publicado: (2022)

Non-motor symptoms in multiple system atrophy: A comparative study with Parkinson's disease and progressive supranuclear palsy
por: Hu, Wen-Zheng, et al.
Publicado: (2023)

Brainstem atrophy in dementia with Lewy bodies compared with progressive supranuclear palsy and Parkinson’s disease on MRI
por: Müller, Sebastian Johannes, et al.
Publicado: (2023)

Clinical outcomes and cognitive impairments between progressive supranuclear palsy and multiple system atrophy
por: Jia, Peifei, et al.
Publicado: (2022)

Genetics of Multiple System Atrophy and Progressive Supranuclear Palsy: A Systemized Review of the Literature
por: Bougea, Anastasia
Publicado: (2023)

Fixel-Based Analysis of White Matter Degeneration in Patients With Progressive Supranuclear Palsy or Multiple System Atrophy, as Compared to Parkinson's Disease
por: Nguyen, Thanh-Thao, et al.
Publicado: (2021)

The Economic Costs of Progressive Supranuclear Palsy and Multiple System Atrophy in France, Germany and the United Kingdom
por: McCrone, Paul, et al.
Publicado: (2011)

Multiscale Entropy of Resting-State Functional Magnetic Resonance Imaging Differentiates Progressive Supranuclear Palsy and Multiple System Atrophy
por: Kadota, Katsuhiko, et al.
Publicado: (2021)

MDS criteria for the diagnosis of progressive supranuclear palsy overemphasize Richardson syndrome
por: Frank, Anika, et al.
Publicado: (2020)

Parkinson disease and progressive supranuclear palsy: protein expression in skin
por: Rodríguez‐Leyva, Ildefonso, et al.
Publicado: (2016)

Sensitivity and Specificity of the ECAS in Parkinson's Disease and Progressive Supranuclear Palsy
por: Foley, Jennifer A., et al.
Publicado: (2018)

Diffusion Tensor Imaging of Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy: A Tract-Based Spatial Statistics Study
por: Worker, Amanda, et al.
Publicado: (2014)

Combination of midbrain-to-pontine ratio and cardiac MIBG scintigraphy to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy
por: Sakuramoto, Hirotaka, et al.
Publicado: (2019)

A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability
por: Rolland, Yan, et al.
Publicado: (2011)

Zolpidem in Progressive Supranuclear Palsy
por: Dash, Sandip K.
Publicado: (2013)

Genetics of Progressive Supranuclear Palsy
por: Im, Sun Young, et al.
Publicado: (2015)

Falls in Progressive Supranuclear Palsy
por: Brown, Fraser S., et al.
Publicado: (2019)

Using Spontaneous Eye-blink Rates to Predict the Motor Status of Patients with Parkinson's Disease
por: Iwaki, Hirotaka, et al.
Publicado: (2019)

Widespread diffusion changes differentiate Parkinson's disease and progressive supranuclear palsy
por: Talai, Aron S., et al.
Publicado: (2018)

Early Impairment of Chopsticks Skills in Parkinsonism Suggests Progressive Supranuclear Palsy
por: Kim, Young Eun, et al.
Publicado: (2020)

Validation of the Parkinson's Disease Caregiver Burden Questionnaire in Progressive Supranuclear Palsy
por: Klietz, Martin, et al.
Publicado: (2021)

Differentiating Progressive Supranuclear Palsy and Parkinson's Disease With Head-Mounted Displays
por: Herwig, Arvid, et al.
Publicado: (2021)

Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning
por: Scotton, William J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3oi17go4gif29ffn3lhb6iq6li